Roquefort Therapeutics plc
Market Cap
$155.54K
P/E Ratio
-0.95
EPS
$-0.01
Dividend Yield
0.00%
52-Week Range
$0.90 — $3.00
Volume
507.20K
Avg Volume
945.47K
Beta
-0.56
Get alerted when ROQ.L hits your target price.
Free — enter your email to get started
P/E (TTM)
-0.95
Forward P/E
—
PEG Ratio
-0.01
P/S (TTM)
0.00
P/B (TTM)
0.03
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.18%
ROA (TTM)
-0.16%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.08
Current Ratio
2.80
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.39%
EPS Growth (5Y)
+0.29%
Sales Growth (3Y)
-0.67%
Sales Growth (5Y)
-0.50%
EPS Est (This Year)
—
EPS Est (Next Year)
—
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.01
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
163.73M
Float
113.84M
Free Float %
69.53%
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
LSE
IPO Date
2021-03-22
Employees
7
CEO
Stephen Paul West
Index Membership
—
Website
https://www.roquefortinvest.com
Roquefort Therapeutics plc (ROQ.L) is a healthcare company in the biotechnology industry listed on the LSE. With a market capitalization of $155.54K, a P/E ratio of -0.95, ROQ.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ROQ.L against other stocks using dozens of fundamental and technical filters.
WINT
Windtree Therapeutics, Inc.
$0.01
-10.00%
$455.07K
CMND
Clearmind Medicine Inc.
$0.94
+15.62%
$128.57K
BCTXZ
BriaCell Therapeutics Corp. Warrant
$0.09
+1.62%
$177.07K
COEPW
Coeptis Therapeutics Holdings, Inc.
$0.01
+0.00%
$72.81K
HEPA
Hepion Pharmaceuticals, Inc.
$0.04
-2.20%
$465.98K
VINC
Vincerx Pharma, Inc.
$0.01
-1.92%
$68.05K
Roquefort Therapeutics plc (ROQ.L) has a trailing twelve-month (TTM) P/E ratio of -0.95. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Roquefort Therapeutics plc (ROQ.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Roquefort Therapeutics plc (ROQ.L) has a market capitalization of $155,540, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.